Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 20 Mar 2018 |
| Orion Corporation: Managers' transactions - Markku Huhta-Koivisto | 2 Mar 2018 |
| Orion Corporation: Managers' transactions - Christer Nordstedt | 2 Mar 2018 |
| Orion Corporation: Managers' transactions - Jari Karlson | 2 Mar 2018 |
| Orion Corporation: Managers' transactions - Liisa Hurme | 2 Mar 2018 |